Navigation Links
AlphaRx's Indaflex(TM) Continues its Clinical Development
Date:5/12/2008

MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that the clinical development of Indaflex(TM), its topical NSAID (Non-Steroidal Anti-Inflammatory Drug) formulation, will continue as part of Cypress Bioscience, Inc. ("Cypress') (NASDAQ: CYPB).

In March 2008, Cypress acquired Proprius Pharmaceuticals, Inc. ("Proprius"). The transaction included an upfront payment of approximately $37.5 million in cash, as well as an additional $37.5 million in potential milestone-related payments associated with the development of Proprius' therapeutic candidates including Indaflex(TM). AlphaRx was notified that the Indaflex licensing agreement has been assigned to Cypress from Proprius as part of that transaction.

Michael Lee, President of AlphaRx stated, "AlphaRx is excited to see the development of Indaflex continue as part of Cypress' on-going clinical development efforts. We believe Indaflex is in good hands and is consistent with Cypress's therapeutic focus and expertise."

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of
'/>"/>

SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Battle Continues Over Vietnam PTSD Numbers
2. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
3. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
4. Securians Minnesota Life Continues to Climb Group Life Rankings
5. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
6. United States continues to have highest level of health spending
7. LehmanMillet Continues Expansion with Strategic Hires
8. American Cancer Society report finds breast cancer death rate continues to drop
9. CIGNA HealthCare Continues Gains in Health Care Quality
10. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
11. Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/20/2008)...- The Scandinavian-based drug,development company...on its,lead antimicrobial candidate LTX-109. Pres...wed that the novel lytic peptidomimetic has an ult...er towards killing Staphylococcus,aureus and Stre...gs. In,addition to this it has proven effective a...
(Date:11/19/2008)...significance , , ISELIN, N.J., Nov. 19 /PR...: PARS ) today announced results from its Phase ... drug delivery technology formulated with 3% Diclo... randomized, double-blinded, placebo-controlled st...ny,s 3% Diclofenac Diethanolamine NanoEmulsion cre...
(Date:11/19/2008)...a contract development and,manufacturing organiza...t,phase launch of its contract facility in Delawa...e process, facility and capacity problems commonly...w-volume clinical and,early-stage commercial ster... invest over $100 million and four years to develo...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Julia Zeitlinger named Pew Scholar 3651 1Julia Zeitlinger named Pew Scholar 3651 2INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 1INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 2AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 1AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 2Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide 28R 29 Tablets 21975 1
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
...ational Reserve" May Also Affect,Alzheimer,s Risk ...e/ -- A new study,suggests that treating risk fact...od pressure and diabetes, may slow the progression...orted today at the,2nd Alzheimer,s Association Int... Washington, DC. , Two new studies presented at th...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
Inquire
...are is easy to configure for gravimetric calibrati...ndard method or enter your own parameters (number ... QualiTrace automatically manages the calibration ...from the balance to the software, which establishe...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile
Reagent Basin, 60mL, 5/Box
Medicine Products: